BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 74264)

  • 1. Tumor immunology: a neurosurgical perspective. II. The immunology of glial neoplasms.
    Apuzzo ML
    Bull Los Angeles Neurol Soc; 1976 Oct; 41(4):176-83. PubMed ID: 74264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aspects of immunobiology and immunotherapy and uses of monoclonal antibodies and biologic immune modifiers in human gliomas.
    Lee Y; Bigner DD
    Neurol Clin; 1985 Nov; 3(4):901-17. PubMed ID: 2417097
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cellular antitumor immune response to a branched lysine multiple antigenic peptide containing epitopes of a common tumor-specific antigen in a rat glioma model.
    Ciesielski MJ; Kazim AL; Barth RF; Fenstermaker RA
    Cancer Immunol Immunother; 2005 Feb; 54(2):107-19. PubMed ID: 15340764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor antigens in astrocytic gliomas.
    Kurpad SN; Zhao XG; Wikstrand CJ; Batra SK; McLendon RE; Bigner DD
    Glia; 1995 Nov; 15(3):244-56. PubMed ID: 8586461
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Monoclonal immunotherapy with human monoclonal antibody(CLN-IgG) in glioma patients].
    Kubo O; Takakura K
    Nihon Rinsho; 2002 Mar; 60(3):497-503. PubMed ID: 11904965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proceedings: Immunological investigations on human brain tumor patients.
    Mahaley MS
    Proc Natl Cancer Conf; 1972; 7():811-5. PubMed ID: 4358071
    [No Abstract]   [Full Text] [Related]  

  • 7. Cell- and peptide-based immunotherapeutic approaches for glioma.
    Yamanaka R
    Trends Mol Med; 2008 May; 14(5):228-35. PubMed ID: 18403264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dendritic cell-based immunotherapy for malignant gliomas.
    Akasaki Y; Black KL; Yu JS
    Expert Rev Neurother; 2005 Jul; 5(4):497-508. PubMed ID: 16026233
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Specific cellular immune responses in patients with malignant gliomas.
    Sheikh KM; Apuzzo ML; Weiss MH
    Cancer Res; 1979 May; 39(5):1733-8. PubMed ID: 85487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms of local immunoresistance in glioma.
    Albesiano E; Han JE; Lim M
    Neurosurg Clin N Am; 2010 Jan; 21(1):17-29. PubMed ID: 19944963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro studies on the cell-mediated immune response to human brain tumors. I. Requirement for third-party stimulator lymphocytes in the induction of cell-mediated cytotoxic responses to allogeneic cultured gliomas.
    Gately MK; Glaser M; Dick SJ; Mettetal RW; Kornblith PL
    J Natl Cancer Inst; 1982 Dec; 69(6):1245-54. PubMed ID: 6183477
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T cell adoptive immunotherapy of newly diagnosed gliomas.
    Plautz GE; Miller DW; Barnett GH; Stevens GH; Maffett S; Kim J; Cohen PA; Shu S
    Clin Cancer Res; 2000 Jun; 6(6):2209-18. PubMed ID: 10873070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytokine gene therapy of gliomas: induction of reactive CD4+ T cells by interleukin-4-transfected 9L gliosarcoma is essential for protective immunity.
    Giezeman-Smits KM; Okada H; Brissette-Storkus CS; Villa LA; Attanucci J; Lotze MT; Pollack IF; Bozik ME; Chambers WH
    Cancer Res; 2000 May; 60(9):2449-57. PubMed ID: 10811123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor immunology. A neurosurgical perspective. I. General concepts of tumor immunology.
    Apuzzo ML; Sheikh KM
    Bull Los Angeles Neurol Soc; 1976 Oct; 41(4):168-75. PubMed ID: 1088581
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunological aspects of experimental brain tumors (review).
    Stavrou D; Bilzer T; Hultén M; Zänker KS; Anzil AP; Haglid KG; Dahme E
    Anticancer Res; 1982; 2(3):151-5. PubMed ID: 6751209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gliomas: new ways of treatment?
    van Acker RE
    Clin Neurol Neurosurg; 1977; 80(2):112-5. PubMed ID: 209922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel immunotherapeutic approaches to glioma.
    Yamanaka R
    Curr Opin Mol Ther; 2006 Feb; 8(1):46-51. PubMed ID: 16506525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generation of anti-idiotypic reagents in the EGFRvIII tumor-associated antigen system.
    Wikstrand CJ; Cole VR; Crotty LE; Sampson JH; Bigner DD
    Cancer Immunol Immunother; 2002 Feb; 50(12):639-52. PubMed ID: 11862416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dendritic cell-based glioma immunotherapy (review).
    Yamanaka R; Yajima N; Abe T; Tsuchiya N; Homma J; Narita M; Takahashi M; Tanaka R
    Int J Oncol; 2003 Jul; 23(1):5-15. PubMed ID: 12792771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Absence of p53 autoantibodies in sera from glioma patients.
    Rainov NG; Dobberstein KU; Fittkau M; Bahn H; Holzhausen HJ; Gantchev L; Burkert W
    Clin Cancer Res; 1995 Jul; 1(7):775-81. PubMed ID: 9816045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.